Brian Alexander, Foundation Medicine CEO (LinkedIn)

Bris­tol My­ers, Foun­da­tion Med­i­cine ex­pand col­lab­o­ra­tion to ex-Turn­ing Point can­cer drug

Roche sub­sidiary Foun­da­tion Med­i­cine has ex­pand­ed a Big Phar­ma col­lab­o­ra­tion around its com­pan­ion di­ag­nos­tic and a po­ten­tial fu­ture block­buster.

The di­ag­nos­tics out­fit put out word Tues­day that it has reached a deal with phar­ma gi­ant Bris­tol My­ers Squibb. With no fi­nan­cials dis­closed, the col­lab­o­ra­tion would see Foun­da­tion Med­i­cine de­vel­op its biop­sy test, known as Foun­da­tionOne CDx, as a com­pan­ion di­ag­nos­tic for Bris­tol My­ers’ still-in­ves­ti­ga­tion­al oral ty­ro­sine ki­nase in­hibitor re­potrec­tinib.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.